Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Abbott |
---|---|
Information provided by: | Abbott |
ClinicalTrials.gov Identifier: | NCT00038662 |
The purpose of this phase II, randomized, double-blind placebo controlled, multi-center study is to evaluate the safety and efficacy of 10 mg atrasentan in hormone naive subjects as measured by rate of rise in the PSA (primary objective).
Condition | Intervention | Phase |
---|---|---|
Prostatic Neoplasms |
Drug: Atrasentan |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Phase 2 Study Evaluating the Safety and Efficacy of Atrasentan (ABT-627) in Men With Hormone Naive Prostate Cancer Exhibiting Early Signs of Biochemical Failure |
Ages Eligible for Study: | 19 Years and older |
Genders Eligible for Study: | Male |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study Director: | Darryl Sleep, M.D. | Abbott |
Study ID Numbers: | M01-366 |
Study First Received: | June 3, 2002 |
Last Updated: | August 10, 2006 |
ClinicalTrials.gov Identifier: | NCT00038662 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Prostatic Diseases Genital Neoplasms, Male Urogenital Neoplasms |
Genital Diseases, Male Hormones Prostatic Neoplasms |
Neoplasms Neoplasms by Site Prostatic Diseases Genital Neoplasms, Male |
Urogenital Neoplasms Genital Diseases, Male Prostatic Neoplasms |